Fenebrutinib, a Bruton’s tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways
Our study enhances the understanding of BTK functions in human microglial signaling that are relevant to MS pathogenesis and suggests that fenebrutinib could attenuate detrimental microglial activity associated with FcγR activation in people with MS.
Authors
- Julie Langlois
- Will Macnair (ORCID: https://orcid.org/0000-0001-6357-0834)
- Roland Schmucki
- Ludovic Collin (ORCID: https://orcid.org/0000-0002-6313-3244)
- Simona Lange (ORCID: https://orcid.org/0009-0008-4124-9212)
- James Keaney
- Christopher Harp (ORCID: https://orcid.org/0000-0001-7000-8743)
- V. Wee Yong (ORCID: https://orcid.org/0000-0002-2600-3563)
- Cenxiao Li
- Martin Ebeling (ORCID: https://orcid.org/0000-0002-0361-4636)
- Jonathan DeGeer (ORCID: https://orcid.org/0000-0001-5009-535X)
- Tania J. J. Sudharshan (ORCID: https://orcid.org/0000-0003-2830-8106)
- Yun‐An Shen
Institutions
- Roche (Switzerland) (CH)
- University of Calgary (CA)
Publication Details
- Journal
- Journal of Neuroinflammation
- Published
- 2024-10-27
- DOI
- https://doi.org/10.1186/s12974-024-03267-5
- Citations
- 16
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 7.01
Funders
- U.S. Department of Defense
- Roche
- F. Hoffmann-La Roche
- Canadian Institutes of Health Research